The use of biomarkers in diagnosis, therapy and prognosis has gained increasing interest
over the last decades. In particular, the analysis of biomarkers in cancer patients within the …

The interleukin-3 receptor alpha chain (IL-3Rα), more commonly referred to as CD123, is
widely overexpressed in various hematological malignancies, including acute myeloid …

Leukemic stem cells (LSCs) in acute myeloid leukemia (AML) represent a low-frequency
subpopulation of leukemia cells that possess stem cell properties distinct from the bulk …

Several immune checkpoint molecules and immune targets in leukemic cells have been
investigated. Recent studies have suggested the potential clinical benefits of immuno …

Metabolic dysregulation underlies malignant phenotypes attributed to cancer stem cells,
such as unlimited proliferation and differentiation blockade. Here, we demonstrate that …

The antileukemic effect of inhibiting bromodomain and extra-terminal domain-containing
(BET-containing) proteins (BETPs) such as BRD4 has largely been largely attributed to …

Deregulation of transcription is a hallmark of acute myeloid leukemia (AML) that drives
oncogenic expression programs and presents opportunities for therapeutic targeting. By …

Acute myeloid leukemia (AML) remains the most lethal of leukemias and a small population
of cells called leukemic stem cells (LSCs) has been associated with disease relapses. Some …

Recently, due to the application of hematopoietic stem cell transplantation and small
molecule inhibitor, the survival of acute leukemia is prolonged. However, the 5 year survival …

Acute myeloid leukemia (AML) is a heterogeneous disease characterized by morphology
and chromosome aberrations with high mortality. Leukemia stem cells (LSCs) in AML played …